Trials / Completed
CompletedNCT01961830
Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers
An Open-label, Single Dose Study to Assess Intrapulmonary Pharmacokinetics of ME1100 Inhalation Solution Administered to Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Meiji Seika Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a single-center, open-label, single-dose study. The primary objective is to determine Epithelial Lining Fluid (ELF) levels of ME1100 after a single orally inhaled dose. The secondary objectives are to determine systemic exposure to inhaled ME1100 and to assess tolerability and safety of a single dose of ME1100 inhalation solution.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ME1100 inhalation solution |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2013-12-01
- First posted
- 2013-10-11
- Last updated
- 2014-06-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01961830. Inclusion in this directory is not an endorsement.